176 related articles for article (PubMed ID: 21698183)
1. Comprehensive analysis of cellular galectin-3 reveals no consistent oncogenic function in pancreatic cancer cells.
Hann A; Gruner A; Chen Y; Gress TM; Buchholz M
PLoS One; 2011; 6(6):e20859. PubMed ID: 21698183
[TBL] [Abstract][Full Text] [Related]
2. Overexpressed galectin-3 in pancreatic cancer induces cell proliferation and invasion by binding Ras and activating Ras signaling.
Song S; Ji B; Ramachandran V; Wang H; Hafley M; Logsdon C; Bresalier RS
PLoS One; 2012; 7(8):e42699. PubMed ID: 22900040
[TBL] [Abstract][Full Text] [Related]
3. Transient gene silencing of galectin-3 suppresses pancreatic cancer cell migration and invasion through degradation of β-catenin.
Kobayashi T; Shimura T; Yajima T; Kubo N; Araki K; Tsutsumi S; Suzuki H; Kuwano H; Raz A
Int J Cancer; 2011 Dec; 129(12):2775-86. PubMed ID: 21448903
[TBL] [Abstract][Full Text] [Related]
4. Expression profiling of Galectin-3-depleted melanoma cells reveals its major role in melanoma cell plasticity and vasculogenic mimicry.
Mourad-Zeidan AA; Melnikova VO; Wang H; Raz A; Bar-Eli M
Am J Pathol; 2008 Dec; 173(6):1839-52. PubMed ID: 18988806
[TBL] [Abstract][Full Text] [Related]
5. CA-125, but not galectin-3, complements CA 19-9 for discriminating ductal adenocarcinoma versus non-malignant pancreatic diseases.
Coppin L; Benomar K; Corfiotti F; Cattan S; Renaud F; Lapere C; Leteurtre E; Vantyghem MC; Truant S; Pigny P
Pancreatology; 2016; 16(1):115-20. PubMed ID: 26613889
[TBL] [Abstract][Full Text] [Related]
6. Galectin-3 Is Implicated in Tumor Progression and Resistance to Anti-androgen Drug Through Regulation of Androgen Receptor Signaling in Prostate Cancer.
Dondoo TO; Fukumori T; Daizumoto K; Fukawa T; Kohzuki M; Kowada M; Kusuhara Y; Mori H; Nakatsuji H; Takahashi M; Kanayama HO
Anticancer Res; 2017 Jan; 37(1):125-134. PubMed ID: 28011482
[TBL] [Abstract][Full Text] [Related]
7. The loss of the p53 activator HIPK2 is responsible for galectin-3 overexpression in well differentiated thyroid carcinomas.
Lavra L; Rinaldo C; Ulivieri A; Luciani E; Fidanza P; Giacomelli L; Bellotti C; Ricci A; Trovato M; Soddu S; Bartolazzi A; Sciacchitano S
PLoS One; 2011; 6(6):e20665. PubMed ID: 21698151
[TBL] [Abstract][Full Text] [Related]
8. RN1, a novel galectin-3 inhibitor, inhibits pancreatic cancer cell growth in vitro and in vivo via blocking galectin-3 associated signaling pathways.
Zhang L; Wang P; Qin Y; Cong Q; Shao C; Du Z; Ni X; Li P; Ding K
Oncogene; 2017 Mar; 36(9):1297-1308. PubMed ID: 27617577
[TBL] [Abstract][Full Text] [Related]
9. Galectin-1 promotes hepatocellular carcinoma and the combined therapeutic effect of OTX008 galectin-1 inhibitor and sorafenib in tumor cells.
Leung Z; Ko FCF; Tey SK; Kwong EML; Mao X; Liu BHM; Ma APY; Fung YME; Che CM; Wong DKH; Lai CL; Ng IO; Yam JWP
J Exp Clin Cancer Res; 2019 Oct; 38(1):423. PubMed ID: 31640796
[TBL] [Abstract][Full Text] [Related]
10. Regulation of prostate cancer progression by galectin-3.
Wang Y; Nangia-Makker P; Tait L; Balan V; Hogan V; Pienta KJ; Raz A
Am J Pathol; 2009 Apr; 174(4):1515-23. PubMed ID: 19286570
[TBL] [Abstract][Full Text] [Related]
11. Galectin-3's Complex Interactions in Pancreatic Ductal Adenocarcinoma: From Cellular Signaling to Therapeutic Potential.
Dimitrijevic Stojanovic M; Stojanovic B; Radosavljevic I; Kovacevic V; Jovanovic I; Stojanovic BS; Prodanovic N; Stankovic V; Jocic M; Jovanovic M
Biomolecules; 2023 Oct; 13(10):. PubMed ID: 37892182
[TBL] [Abstract][Full Text] [Related]
12. Galectin-4 Reduces Migration and Metastasis Formation of Pancreatic Cancer Cells.
Belo AI; van der Sar AM; Tefsen B; van Die I
PLoS One; 2013; 8(6):e65957. PubMed ID: 23824659
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of Galectin-3 and its clinical significance in ovarian carcinoma.
Kim MK; Sung CO; Do IG; Jeon HK; Song TJ; Park HS; Lee YY; Kim BG; Lee JW; Bae DS
Int J Clin Oncol; 2011 Aug; 16(4):352-8. PubMed ID: 21327452
[TBL] [Abstract][Full Text] [Related]
14. Gene silencing of galectin-3 changes the biological behavior of Eca109 human esophageal cancer cells.
Qiao L; Liang N; Xie J; Luo H; Zhang J; Deng G; Li Y; Zhang J
Mol Med Rep; 2016 Jan; 13(1):160-6. PubMed ID: 26718452
[TBL] [Abstract][Full Text] [Related]
15. Phosphorylation of galectin-3 contributes to malignant transformation of human epithelial cells via modulation of unique sets of genes.
Mazurek N; Sun YJ; Price JE; Ramdas L; Schober W; Nangia-Makker P; Byrd JC; Raz A; Bresalier RS
Cancer Res; 2005 Dec; 65(23):10767-75. PubMed ID: 16322222
[TBL] [Abstract][Full Text] [Related]
16. Overexpressed EDIL3 predicts poor prognosis and promotes anchorage-independent tumor growth in human pancreatic cancer.
Jiang SH; Wang Y; Yang JY; Li J; Feng MX; Wang YH; Yang XM; He P; Tian GA; Zhang XX; Li Q; Cao XY; Huo YM; Yang MW; Fu XL; Li J; Liu DJ; Dai M; Wen SY; Gu JR; Hong J; Hua R; Zhang ZG; Sun YW
Oncotarget; 2016 Jan; 7(4):4226-40. PubMed ID: 26735172
[TBL] [Abstract][Full Text] [Related]
17. MED29, a component of the mediator complex, possesses both oncogenic and tumor suppressive characteristics in pancreatic cancer.
Kuuselo R; Savinainen K; Sandström S; Autio R; Kallioniemi A
Int J Cancer; 2011 Dec; 129(11):2553-65. PubMed ID: 21225629
[TBL] [Abstract][Full Text] [Related]
18. Galectin-8 promotes migration and proliferation and prevents apoptosis in U87 glioblastoma cells.
Metz C; Döger R; Riquelme E; Cortés P; Holmes C; Shaughnessy R; Oyanadel C; Grabowski C; González A; Soza A
Biol Res; 2016 Jul; 49(1):33. PubMed ID: 27459991
[TBL] [Abstract][Full Text] [Related]
19. Galectin-3 Mediates Tumor Cell-Stroma Interactions by Activating Pancreatic Stellate Cells to Produce Cytokines via Integrin Signaling.
Zhao W; Ajani JA; Sushovan G; Ochi N; Hwang R; Hafley M; Johnson RL; Bresalier RS; Logsdon CD; Zhang Z; Song S
Gastroenterology; 2018 Apr; 154(5):1524-1537.e6. PubMed ID: 29274868
[TBL] [Abstract][Full Text] [Related]
20. Expression of galectin-3 in pancreatic ductal adenocarcinoma.
Gaida MM; Bach ST; Günther F; Baseras B; Tschaharganeh DF; Welsch T; Felix K; Bergmann F; Hänsch GM; Wente MN
Pathol Oncol Res; 2012 Apr; 18(2):299-307. PubMed ID: 21910036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
